Armstrong Fleming & Moore’s Pfizer PFE Stock Holding History

Armstrong Fleming & Moore’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-9,868	Closed	-$277K	–	118
2026 Q1	$277K	Buy	9,868 +70	+0.7%	+$1.86K	0.12%	87
2025 Q4	$244K	Sell	9,798 -57	-0.6%	-$1.44K	0.11%	89
2025 Q3	$251K	Hold	9,855	–	–	0.12%	91
2025 Q2	$239K	Buy	+9,855	New	+$230K	0.13%	90
2025 Q1	–	Sell	-11,802	Closed	-$313K	–	137
2024 Q4	$313K	Sell	11,802 -707	-6%	-$19.2K	0.19%	76
2024 Q3	$362K	Buy	12,509 +500	+4%	+$14.6K	0.21%	69
2024 Q2	$336K	Sell	12,009 -126	-1%	-$3.47K	0.22%	68
2024 Q1	$337K	Hold	12,135	–	–	0.23%	73
2023 Q4	$349K	Hold	12,135	–	–	0.26%	68
2023 Q3	$403K	Hold	12,135	–	–	0.39%	57
2023 Q2	$445K	Buy	+12,135	New	+$472K	0.41%	54

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Armstrong Fleming & Moore's PFE Position: Q2 2026 in Review

Armstrong Fleming & Moore sold out of Pfizer (PFE) in Q2 2026, closing a stake of 9,868 shares — an estimated $277K sold.

Armstrong Fleming & Moore first reported a position in PFE in Q2 2023 and held it in 11 quarters. The position peaked at $445K in Q2 2023. 2,827 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

Armstrong Fleming & Moore reported no remaining Pfizer position as of Q2 2026 after selling out during the quarter.
Armstrong Fleming & Moore sold 9,868 Pfizer shares in Q2 2026, an estimated $277K.
Armstrong Fleming & Moore first reported a position in Pfizer in Q2 2023 and held it in 11 quarters.
Armstrong Fleming & Moore's Pfizer position peaked at $445K in Q2 2023.
2,827 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Armstrong Fleming & Moore's 13F filing for Q2 2026, filed 28 Jul 2026.